Opioids for low back pain

Richard (Rick) Deyo, Michael Von Korff, David Duhrkoop

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Back pain affects most adults, causes disability for some, and is a common reason for seeking healthcare. In the United States, opioid prescription for low back pain has increased, and opioids are now the most commonly prescribed drug class. More than half of regular opioid users report back pain. Rates of opioid prescribing in the US and Canada are two to three times higher than in most European countries. The analgesic efficacy of opioids for acute back pain is inferred from evidence in other acute pain conditions. Opioids do not seem to expedite return to work in injured workers or improve functional outcomes of acute back pain in primary care. For chronic back pain, systematic reviews find scant evidence of efficacy. Randomized controlled trials have high dropout rates, brief duration (four months or less), and highly selected patients. Opioids seem to have short term analgesic efficacy for chronic back pain, but benefits for function are less clear. The magnitude of pain relief across chronic non-cancer pain conditions is about 30%. Given the brevity of randomized controlled trials, the long term effectiveness and safety of opioids are unknown. Loss of long term efficacy could result from drug tolerance and emergence of hyperalgesia. Complications of opioid use include addiction and overdose related mortality, which have risen in parallel with prescription rates. Common short term side effects are constipation, nausea, sedation, and increased risk of falls and fractures. Longer term side effects may include depression and sexual dysfunction. Screening for high risk patients, treatment agreements, and urine testing have not reduced overall rates of opioid prescribing, misuse, or overdose. Newer strategies for reducing risks include more selective prescription of opioids and lower doses; use of prescription monitoring programs; avoidance of co-prescription with sedative hypnotics; and reformulations that make drugs more difficult to snort, smoke, or inject.

Original languageEnglish (US)
Article numberg6380
JournalBMJ (Online)
Volume350
DOIs
StatePublished - Jan 5 2015

Fingerprint

Low Back Pain
Opioid Analgesics
Back Pain
Prescriptions
Acute Pain
Chronic Pain
Randomized Controlled Trials
Drug Tolerance
Pain
Return to Work
Hyperalgesia
Constipation
Hypnotics and Sedatives
Smoke
Pharmaceutical Preparations
Nausea
Canada
Analgesics
Primary Health Care
Urine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Deyo, R. R., Von Korff, M., & Duhrkoop, D. (2015). Opioids for low back pain. BMJ (Online), 350, [g6380]. https://doi.org/10.1136/bmj.g6380

Opioids for low back pain. / Deyo, Richard (Rick); Von Korff, Michael; Duhrkoop, David.

In: BMJ (Online), Vol. 350, g6380, 05.01.2015.

Research output: Contribution to journalArticle

Deyo, RR, Von Korff, M & Duhrkoop, D 2015, 'Opioids for low back pain', BMJ (Online), vol. 350, g6380. https://doi.org/10.1136/bmj.g6380
Deyo RR, Von Korff M, Duhrkoop D. Opioids for low back pain. BMJ (Online). 2015 Jan 5;350. g6380. https://doi.org/10.1136/bmj.g6380
Deyo, Richard (Rick) ; Von Korff, Michael ; Duhrkoop, David. / Opioids for low back pain. In: BMJ (Online). 2015 ; Vol. 350.
@article{938769b5dcbd436b8e8dad14a7624bd2,
title = "Opioids for low back pain",
abstract = "Back pain affects most adults, causes disability for some, and is a common reason for seeking healthcare. In the United States, opioid prescription for low back pain has increased, and opioids are now the most commonly prescribed drug class. More than half of regular opioid users report back pain. Rates of opioid prescribing in the US and Canada are two to three times higher than in most European countries. The analgesic efficacy of opioids for acute back pain is inferred from evidence in other acute pain conditions. Opioids do not seem to expedite return to work in injured workers or improve functional outcomes of acute back pain in primary care. For chronic back pain, systematic reviews find scant evidence of efficacy. Randomized controlled trials have high dropout rates, brief duration (four months or less), and highly selected patients. Opioids seem to have short term analgesic efficacy for chronic back pain, but benefits for function are less clear. The magnitude of pain relief across chronic non-cancer pain conditions is about 30{\%}. Given the brevity of randomized controlled trials, the long term effectiveness and safety of opioids are unknown. Loss of long term efficacy could result from drug tolerance and emergence of hyperalgesia. Complications of opioid use include addiction and overdose related mortality, which have risen in parallel with prescription rates. Common short term side effects are constipation, nausea, sedation, and increased risk of falls and fractures. Longer term side effects may include depression and sexual dysfunction. Screening for high risk patients, treatment agreements, and urine testing have not reduced overall rates of opioid prescribing, misuse, or overdose. Newer strategies for reducing risks include more selective prescription of opioids and lower doses; use of prescription monitoring programs; avoidance of co-prescription with sedative hypnotics; and reformulations that make drugs more difficult to snort, smoke, or inject.",
author = "Deyo, {Richard (Rick)} and {Von Korff}, Michael and David Duhrkoop",
year = "2015",
month = "1",
day = "5",
doi = "10.1136/bmj.g6380",
language = "English (US)",
volume = "350",
journal = "BMJ (Online)",
issn = "0267-0623",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Opioids for low back pain

AU - Deyo, Richard (Rick)

AU - Von Korff, Michael

AU - Duhrkoop, David

PY - 2015/1/5

Y1 - 2015/1/5

N2 - Back pain affects most adults, causes disability for some, and is a common reason for seeking healthcare. In the United States, opioid prescription for low back pain has increased, and opioids are now the most commonly prescribed drug class. More than half of regular opioid users report back pain. Rates of opioid prescribing in the US and Canada are two to three times higher than in most European countries. The analgesic efficacy of opioids for acute back pain is inferred from evidence in other acute pain conditions. Opioids do not seem to expedite return to work in injured workers or improve functional outcomes of acute back pain in primary care. For chronic back pain, systematic reviews find scant evidence of efficacy. Randomized controlled trials have high dropout rates, brief duration (four months or less), and highly selected patients. Opioids seem to have short term analgesic efficacy for chronic back pain, but benefits for function are less clear. The magnitude of pain relief across chronic non-cancer pain conditions is about 30%. Given the brevity of randomized controlled trials, the long term effectiveness and safety of opioids are unknown. Loss of long term efficacy could result from drug tolerance and emergence of hyperalgesia. Complications of opioid use include addiction and overdose related mortality, which have risen in parallel with prescription rates. Common short term side effects are constipation, nausea, sedation, and increased risk of falls and fractures. Longer term side effects may include depression and sexual dysfunction. Screening for high risk patients, treatment agreements, and urine testing have not reduced overall rates of opioid prescribing, misuse, or overdose. Newer strategies for reducing risks include more selective prescription of opioids and lower doses; use of prescription monitoring programs; avoidance of co-prescription with sedative hypnotics; and reformulations that make drugs more difficult to snort, smoke, or inject.

AB - Back pain affects most adults, causes disability for some, and is a common reason for seeking healthcare. In the United States, opioid prescription for low back pain has increased, and opioids are now the most commonly prescribed drug class. More than half of regular opioid users report back pain. Rates of opioid prescribing in the US and Canada are two to three times higher than in most European countries. The analgesic efficacy of opioids for acute back pain is inferred from evidence in other acute pain conditions. Opioids do not seem to expedite return to work in injured workers or improve functional outcomes of acute back pain in primary care. For chronic back pain, systematic reviews find scant evidence of efficacy. Randomized controlled trials have high dropout rates, brief duration (four months or less), and highly selected patients. Opioids seem to have short term analgesic efficacy for chronic back pain, but benefits for function are less clear. The magnitude of pain relief across chronic non-cancer pain conditions is about 30%. Given the brevity of randomized controlled trials, the long term effectiveness and safety of opioids are unknown. Loss of long term efficacy could result from drug tolerance and emergence of hyperalgesia. Complications of opioid use include addiction and overdose related mortality, which have risen in parallel with prescription rates. Common short term side effects are constipation, nausea, sedation, and increased risk of falls and fractures. Longer term side effects may include depression and sexual dysfunction. Screening for high risk patients, treatment agreements, and urine testing have not reduced overall rates of opioid prescribing, misuse, or overdose. Newer strategies for reducing risks include more selective prescription of opioids and lower doses; use of prescription monitoring programs; avoidance of co-prescription with sedative hypnotics; and reformulations that make drugs more difficult to snort, smoke, or inject.

UR - http://www.scopus.com/inward/record.url?scp=84921415780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921415780&partnerID=8YFLogxK

U2 - 10.1136/bmj.g6380

DO - 10.1136/bmj.g6380

M3 - Article

C2 - 25561513

AN - SCOPUS:84921415780

VL - 350

JO - BMJ (Online)

JF - BMJ (Online)

SN - 0267-0623

M1 - g6380

ER -